traži (Vijesti)

Palvella Therapeutics Announces Positive Topline Results From Phase 3 SELVA Clinical Study Of QTORINTM 3.9% Rapamycin Anhydrous Gel (QTORINTM Rapamycin) In Microcystic Lymphatic Malformations

top health

(MENAFN - GlobeNewsWire - Nasdaq) Primary endpoint met with statistically significant improvement (mean change of +2.13; p Achieved statistical significance on pre-specified key secondary endpoint ...
2026-02-24 06:31:35